Subscribe or Manage Preferences
VBCR - Conference Highlights - ACR 2013, Lupus

Elevation of interferon type I (IFN-I) is associated with more severe disease in patients with systemic lupus erythematosus (SLE), although the relationship between elevated levels of IFN-I and SLE disease activity over time has not been defined. In particular, lupus nephritis is the most common severe manifestation of SLE and confers an increased risk for end-stage renal disease and death in patients with SLE. In a new retrospective study, Kirou and colleagues (ACR 2013; Abstract 1572) analyzed plasma samples from 57 patients with SLE for IFN-I levels, as well as clinical and other laboratory data, longitudinally over an average of 9 visits per patient. The IFN-I levels were analyzed based on the response of the WISH cell line to SLE patient plasma, which is sensitive to IFN-I stimulation and has a minimum detection level of 6 IU/mL when assayed using quantitative PCR. Normal plasma and a recombinant IFN-I standard were used as negative and positive controls, respectively.  The patients were divided into 2 groups based on high or low IFN-I levels at baseline (study initiation).

Patients with SLE and high IFN-I plasma activity at baseline showed a 3.2-fold increased IFN-I plasma activity during follow-up visits compared with patients with low IFN-I plasma activity at baseline (P <.01). Compared with patients with low IFN-I plasma activity at baseline, the patients with high IFN-I plasma activity had significant decreases in peripheral blood C3 levels (P <.03), white blood cell counts (P <.04), absolute lymphocyte counts (P <.01), and a higher erythrocyte sedimentation rate (P <.02) and anti–ds-DNA titers (P <.02). Patients with high plasma IFN-I activity at the first study visit exhibited 1.4-fold greater disease activity during the study as measured by the SLE Disease Activity Index (SLEDAI; P <.02) or the British Isles Lupus Assessment Group (BILAG; P <.05).

Strikingly, patients with SLE and high IFN-I activity at study initiation demonstrated a 2.5-fold increase in renal BILAG activity (which can translate to a greater likelihood of developing lupus nephritis and end-stage renal disease), a 1.8-fold increase in neurologic BILAG activity, and worsened hematologic BILAG scores.

The authors concluded that measurement of IFN-I activity in plasma of patients with SLE may help identify patients at high risk for lupus nephritis and thus serve as an important disease monitoring biomarker. Furthermore, IFN-I appears to predict increased disease activity in neurologic and hematologic systems as detected by BILAG scores. However, for these conclusions to be useful, the measurement of plasma IFN-I must be made readily available and affordable for routine clinical practice.

Related Items
New Evidence of Racial and Ethnic Disparities Among Patients with Systemic Lupus Erythematosus
VBCR - October 2017, Vol 6, No 4 published on October 20, 2017 in Lupus
New Electronic Health Record Algorithms Accurately Identify Patients with Systemic Lupus Erythematosus
Alice Goodman
VBCR - June 2017, Vol 6, No 2 published on June 29, 2017 in Lupus
Patients with Systemic Lupus Erythematosus Should Be Monitored for Electrocardiogram Abnormalities
Alice Goodman
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Lupus
Addressing Health Issues in Women with Systemic Lupus Erythematosus and/or Antiphospholipid Syndrome
Sophie Granger
VBCR - April 2017, Vol 6, No 1 published on May 3, 2017 in Lupus
Mixed Cost Results with Repository Corticotropin Injection Therapy for Patients with SLE
Charles Bankhead
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Cervical Neoplasia Screening Needed in Women with Systemic Lupus Erythematosus
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Anifrolumab a Winner, So Far, for Severe Systemic Lupus Erythematosus
Alice Goodman
VBCR - August 2016, Vol 5, No 4 published on August 25, 2016 in Lupus
Age, Smoking History Are Risk Factors for Early Organ Damage in Patients with SLE
Phoebe Starr
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Lupus
5 Tips for Preventing Lupus Flares
VBCR - June 2016, Vol 5, No 3 published on July 7, 2016 in Lupus
Exercise, Psychotherapy Can Reduce Fatigue in Patients with Systemic Lupus Erythematosus
Alice Goodman
VBCR - February 2016, Vol 5, No 1 published on March 15, 2016 in Lupus
Last modified: May 21, 2015
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology